Half year report 2022

The Galenica Group experienced strong operational growth in the first half of 2022 and, at the same time, has driven forward the implementation of its strategy with targeted acquisitions.

Foreword

«We are actively shaping the digitalisation of the health system and driving forward the networking of all stakeholders.»

Foreword

Key figures

In the first half of 2022, the Galenica Group generated consolidated net sales of CHF 1,959.9 million, representing strong growth of 5.5% compared to the first half of 2021.

1,959.9

Net sales

in million CHF

100.0

EBIT adjusted²

in million CHF

7,314

Number of employees

at 30 June 2022

Management report

Galenica grows strongly
in the first half year

The lifting of the coronavirus measures had a positive impact on the business performance of the Group as a whole in the first half of 2022. A normal flu season and numerous illnesses caused by the coronavirus Omicron variant led to strong sales growth in OTC cold medication.

Customers

Our patients and customers are at the heart of what we do. And this is at the core of our customer promise: «We support people at every stage of life on their journey towards health and well-being.»

Customers

Business Development

Galenica’s strategic programmes are focused on offering customers and patients the best customer experience across all channels.

Business Development

Employees

The Galenica Group supports its employees to develop their skills and realise their full potential – also with the aim of being an attractive employer and attracting and retaining valuable specialists.

Employees

Sustainability

Sustainability is an integral part of Galenica's corporate management and strategy. We are aware of our economic, social and environmental responsibility and have therefore further strengthened our commitment to sustainability.

Sustainability

Half year report 2022

Galenica grows strongly in the first half year

Galenica grows strongly
in the first half year